No Data
Saito Biotech: Report for the third quarter of 2024
Express News | Shandong Sito Bio-technology: The company's operation is normal.
Saito Biotech: 2024 Semi-Annual Report
Saito Biotech: 2024 Semi-Annual Report Summary
Shandong Sito Bio-Technology (300583.SZ): The net income in the first half of the year was 13.2114 million yuan, a year-on-year decrease of 77.97%.
On August 26th, Shandong Sito Bio-Technology (300583.SZ) released its semi-annual report for 2024. During the reporting period, the total operating revenue was 0.567 billion yuan, a decrease of 14.62% year-on-year. The net income attributable to shareholders of the listed company was 13.2114 million yuan, a decrease of 77.97% year-on-year. After deducting non-recurring gains and losses, the net income attributable to shareholders of the listed company was 5.05 million yuan, a decrease of 86.40% year-on-year. The basic earnings per share were 0.07 yuan.
Shandong Sito Bio-Technology (300583.SZ): Budesonide received the approval notice for the active pharmaceutical ingredient application for marketing.
On August 19th, Gelon Hui reported that Shandong Sito Bio-technology (300583.SZ), a subsidiary of the company, received the approval notice of budesonide active pharmaceutical ingredient for marketing application issued by the National Medical Products Administration. Budesonide API can be used to produce various dosage forms of drugs such as budesonide inhalation powder, inhalation aerosol, inhalation suspension and nasal spray. Budesonide is a glucocorticoid with highly effective localized anti-inflammatory and anti-allergic effects, which is clinically used to treat asthma, allergic rhinitis and prevent and treat nasal polyps.
No Data
No Data